Navigation Links
ev3 Inc. Appoints John L. Miclot to Board of Directors

PLYMOUTH, Minn., Dec. 3 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV), a global endovascular device company, today announced the appointment of John L. Miclot to its Board of Directors effective immediately.

Mr. Miclot is currently the president and chief executive officer of CCS Medical, a privately held nationwide provider of various home care products for chronic diseases such as diabetes, wound care, urology and respiratory disorders. Prior to joining CCS Medical, Mr. Miclot served as chief executive officer of Philips Home Healthcare Solutions from March 2008 until November 2008 following the acquisition of Respironics, Inc. by Philips. From December 2003 to March 2008, Miclot served as president and chief executive officer of Respironics, Inc. Prior to that, Mr. Miclot served in various positions at Respironics, Inc. from 1998 to 2003, including chief strategic officer and president of the Homecare Division. Mr. Miclot joined Respironics in 1998 when it acquired Healthdyne Technologies where he had served as senior vice president, sales and marketing from 1995 to 1998.

Mr. Miclot currently serves on the board of directors of Wright Medical Group and several private companies including CCS Medical.

"We are delighted to have someone with John's proven leadership skills and extensive operational expertise join our board," said Robert Palmisano, president and chief executive officer of ev3. "John's insight and experience will be of great value as we work towards building the premier endovascular company and preferred physician partner for identifying and treating peripheral vascular and neurovascular disease."

About ev3 Inc.

Since its founding in 2000, ev3 has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. ev3's products are used by endovascular specialists to treat a wide range of peripheral vascular and neurovascular diseases and disorders. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today -- peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at

ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
2. BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
3. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
4. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
5. InCode BioPharmaceutics Appoints New President and CEO
6. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
7. GeneNews appoints Canadian Colorectal Cancer Advisory Board
8. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
9. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
10. Accumetrics Appoints John J. Young, MD Chief Medical Officer
11. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: ... developing DCVax® personalized immune therapies for solid tumor cancers, ... an additional independent director, and the Company welcomes ... allegations in a recent anonymous internet report on NW ... initiatives. Linda Powers stated, "We agree ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
Breaking Biology Technology:
(Date:11/4/2015)... --> --> ... Transparency Market Research "Home Security Solutions Market - Global Industry ... 2022", the global home security solutions market is expected to reach ... market is estimated to expand at a CAGR of ... Rising security needs among customers at homes, the emergence ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/29/2015)... NEW YORK , Oct. 29, 2015 /PRNewswire/ ... wearable technology, announced a partnership with 2XU, a ... accessories, to deliver a smart hat with advanced ... runners and other athletes to monitor key biometrics ... of the strategic partnership, the two companies will bring ...
Breaking Biology News(10 mins):